Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer
1. 系统已在2026-04-23 11:35:39对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/jco-24-01989
文献链接: https://ascopubs.org/doi/10.1200/JCO-24-01989
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Rahul R. Aggarwal; Jacqueline Vuky; David VanderWeele; Matthew Rettig; Elisabeth I. Heath; David Quigley; Jiaoti Huang; Arun Chumber; Alexander Cheung; Adam Foye; Stanley Leung; Jill Abbey; Andrew Dorr; Marc Nasoff; John Hunter; Steven Wang; Robert R. Flavell; Lawrence Fong; Bin Liu; Eric J. Small

